MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD

NCT02534766 | Completed

• 1 other identifier: PHT/2015/71
• Study Type: observational
• Target: 114
• Locations: 1 country
• Sites: 1

Brief Summary

MISSION is a new and novel way of delivering highly specialised Chronic Obstructive Pulmonary Disease (COPD) care and has the potential to change the way COPD care across the UK is delivered as well as services for other long term health conditions. The MISSION model has been piloted in asthma which is the subject of an ongoing research study. This is the first model of this type in COPD and the current research study aims to evaluate the outcomes of the project. This will be done in several different ways. The study is a mixed methods evaluation of the new service comparing outcomes before and after the clinic using retrospective data analysis and prospective qualitative interview. The study will be conducted at Portsmouth Hospitals NHS Trust and will recruit patients who attend MISSION COPD clinics as well as staff who attended MISSION clinics in a professional capacity.

Conditions

Pulmonary Disease, Chronic Obstructive

Outcome Measures

Primary Outcomes (4)

• COPD control measured by number of exacerbations treated with steroids and or antibiotics for ≥3 days

  To assess whether the number COPD exacerbations (prednisolone or equivalent ≥30 mg for \>3 days or antibiotics for \>3 days) improves in MISSION patients in the 6 months after the clinic compared with the 6 months before.

  6 months previous

• COPD control measured by number of exacerbations treated with steroids and or antibiotics for ≥3 days

  To assess whether the number COPD exacerbations (prednisolone or equivalent ≥30 mg for \>3 days or antibiotics for \>3 days) improves in MISSION patients in the 6 months after the clinic compared with the 6 months before.

  6 months

• Number of exacerbations of COPD that require hospital admission and treatment

  Number of exacerbations of COPD that require admission to hospital for treatment to assess whether hospital admissions change in the 6 months after the MISSION clinic

  6 months previous

• Number of exacerbations of COPD that require hospital admission and treatment

  Number of exacerbations of COPD that require admission to hospital for treatment to assess whether hospital admissions change in the 6 months after the MISSION clinic

  6 months

Secondary Outcomes (38)

• COPD Assessment Test (CAT) Score

  baseline

• COPD Assessment Test (CAT) Score

  3 months

• COPD Assessment Test (CAT) Score

  6 months

• St George's Respiratory Questionnaire (SGRQ)

  baseline

• St George's Respiratory Questionnaire (SGRQ)

  3 months

Study Arms (2)

Patients who attended the MISSION COPD clinics

COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team

Health Care Professionals

Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be patients who attend MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team or health care professionals who attend the clinic in a clinical capacity.

You may qualify if:

• Male of Female, aged 18 years or above.
• Attended the MISSION clinic as a patient.
• Participant is willing and able to give informed consent for participation in the study.

You may not qualify if:

• \- The patient is unable or unwilling to give consent
• Male or Female, aged 18 or above.
• Attended the MISSION clinic as a health care professional
• Participant is willing and able to give informed consent for participation in the study.
• \- The health care professional is unable or unwilling to give consent

Sponsors & Collaborators

• Portsmouth Hospitals NHS Trust: lead
• Pfizer: collaborator

Study Sites (1)

Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital

Portsmouth, Hampshire, PO6 3LY, United Kingdom

Location

Related Publications (2)

• Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van Molken M, Chavannes NH. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Oct 10;(10):CD009437. doi: 10.1002/14651858.CD009437.pub2.

  PMID: 24108523 BACKGROUND

• Wilkinson T, North M, Bourne SC. Reducing hospital admissions and improving the diagnosis of COPD in Southampton City: methods and results of a 12-month service improvement project. NPJ Prim Care Respir Med. 2014 Aug 21;24(0):14035. doi: 10.1038/npjpcrm.2014.35.

  PMID: 25141877 BACKGROUND

Related Links

• Department of Health, 2011. An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England
• Public Health England, 2014. Portsmouth Unitary Authority Health Profile 2014
• Public Health England, 2015. Local Tobacco Control Proflies.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Professor Anoop J Chauhan

  Portsmouth Hospitals NHS Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 25, 2015
• First Posted: August 28, 2015
• Study Start: September 1, 2015
• Primary Completion: August 1, 2016
• Study Completion: August 1, 2016
• Last Updated: September 27, 2016

Record last verified: 2016-09

Locations

GB (1)